School Readiness Intervention for Preschool Children With Sickle Cell Disease
Part of paid clinical trials in Memphis, Tennessee.
- Sponsor
- St. Jude Children's Research Hospital
- Study ID
- NCT06367192
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 42 Months - 78 Months
- Healthy Volunteers
- Not accepted
Interventions
- The adapted Kids in Transition to School Intervention — BEHAVIORALAn intensive, school readiness intervention designed to improve preschoolers' social skills, early literacy, numeracy, and self-regulation skills at high risk for academic difficulties. The intervention is delivered virtually over 8 weeks with caregivers and intentionally occurs over the summer when there is a gap in preschool services.
- Standard school resources — BEHAVIORALInformation about local preschool programs and age appropriate books for children will be provided.
Study Details
The study participant is being asked to take part in this clinical trial, a type of research study, because the participant is a young child with sickle cell disease or the caregiver of a child with sickle cell disease. This study is being done to test a school readiness program for children with sickle cell disease (ages 3.5-6,5 years old). Primary Objective Assess feasibility and acceptability of an adapted school readiness intervention among preschool children (ages 3.5-6.5) diagnosed with sickle cell disease. Secondary Objectives Objective 1: Measure preliminary efficacy of the adapted school readiness intervention compared to routine care among preschool children ages (3.5-6.5) diagnosed with sickle cell disease. Objective 2: Examine implementation factors (i.e., barriers and facilitators) during post-intervention.
Key Dates
- Start date
- Mar 31, 2025
- Status verified
- Apr 2026
- Primary completion
- Oct 31, 2026
- Completion
- Oct 31, 2028
Study Design
- Enrollment
- 36 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Readiness Intervention* Attend virtual classroom program sessions- If participants are in the school readiness group, the caregiver, will attend about 8 weeks of sessions virtually with a teacher or social worker and a caregiver of a child with sickle cell, for a total of 8 sessions. The sessions will be during the summer and done in a group. Each session will last about 1 ½ hours and will be video recorded. \> •Complete a caregiver interview-If participants are in the school readiness group, a member of the study team will interview you after the virtual classroom sessions are over. The interview will take about 15-20 minutes and will be audio recorded. Participants will be asked for suggestions and how satisfied you were with the program. * Complete assessments - Caregiver and participant will complete a set of assessments that evaluate school readiness skills (e.g., early math and reading), child behaviors, and parent-child relationships before and after the intervention.
- Other: Control: Standard school resourcesParents will be provided with information about preschool programs available in the community and age appropriate books for their children
Primary Outcome Measure
Feasibility of Intervention Measure [ Time Frame: Collected immediately after the intervention ]
Central Contacts
- ANDREW HEITZER, PhD888-226-4343
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | ANDREW HEITZER, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Memphis, TN
Related Studies
- Sickle Cell Clinical Research and Intervention ProgramRecruiting · St. Jude Children's Research Hospital · Peoria, Illinois
- Investigation of the Genetics of Hematologic DiseasesRecruiting · St. Jude Children's Research Hospital · Memphis, Tennessee
- Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell DiseaseRecruiting · St. Jude Children's Research Hospital · Memphis, Tennessee
- A Long-term Follow-up Study in Participants Who Received CTX001PHASE3 · Enrolling By Invitation · Vertex Pharmaceuticals Incorporated · Palo Alto, California